{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:40:10Z","timestamp":1792834810228,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.resinv.2026.101528","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:55:41Z","timestamp":1792720541000},"page":"101528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypoxemia and pulmonary infiltrates during T-cell-engaging bispecific antibody therapy: A pulmonary and critical care framework"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-5029","authenticated-orcid":false,"given":"Aryan","family":"Shiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman O.","family":"Soubani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101528_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2026.101528_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib3","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2026.101528_bib4","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: teclistamab - a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2026.101528_bib5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2026.101528_bib6","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2026.101528_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70442","article-title":"Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: a US subgroup analysis from MagnetisMM-3","author":"Nooka","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2026.101528_bib8","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib9","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel subcutaneous CD3 x CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-026-06798-4","article-title":"Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial","volume":"105","author":"Karimi","year":"2026","journal-title":"Ann Hematol"},{"key":"10.1016\/j.resinv.2026.101528_bib12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib13","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin versus rituximab-gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3 randomized trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2026.101528_bib14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.resinv.2026.101528_bib15","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.resinv.2026.101528_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.resinv.2026.101528_bib17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.resinv.2026.101528_bib20","series-title":"IMDELLTRA (Tarlatamab-dlle) prescribing information","year":"2026"},{"key":"10.1016\/j.resinv.2026.101528_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102889","article-title":"Diagnosis and management of bispecific T cell-engaging antibody toxicity: a primer for emergency physicians","volume":"134","author":"Wattana","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.resinv.2026.101528_bib22","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with multiple myeloma receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.resinv.2026.101528_bib24","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group Immunotherapy Committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3 x CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2026.101528_bib26","series-title":"Prevention and treatment of cancer-related Infections. NCCN Clinical Practice Guidelines in oncology","year":"12026"},{"key":"10.1016\/j.resinv.2026.101528_bib27","series-title":"Management of CAR T-Cell and lymphocyte engager-related Toxicities. NCCN Clinical Practice Guidelines in oncology","year":"22026"},{"key":"10.1016\/j.resinv.2026.101528_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.resinv.2026.101528_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.resinv.2026.101528_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-025-00677-4","article-title":"Cytokine storm","volume":"12","author":"Karki","year":"2026","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.resinv.2026.101528_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2039432","article-title":"Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.resinv.2026.101528_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.resinv.2026.101528_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/cpt.3751","article-title":"Tocilizumab dosing for management of T cell-engaging bispecific antibody-related CRS in patients with relapsed\/refractory B-cell Non-Hodgkin lymphoma","volume":"118","author":"Jamois","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.resinv.2026.101528_bib34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.resinv.2026.101528_bib35","article-title":"Infection risk associated with teclistamab in relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence","volume":"17","author":"Huang","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101528_bib36","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.resinv.2026.101528_bib37","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.resinv.2026.101528_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma: an International Myeloma Working Group study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.resinv.2026.101528_bib39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.resinv.2026.101528_bib40","first-page":"656","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","volume":"111","author":"Cani","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.resinv.2026.101528_bib41","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.resinv.2026.101528_bib42","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2024.42.16_suppl.7528","article-title":"OPTec: a phase 2 study to evaluate outpatient step-up administration of teclistamab, a BCMA-targeting bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Rifkin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.27618","article-title":"Balancing the scales: optimizing reporting of infection rates in clinical trials of bispecific antibodies in multiple myeloma","volume":"100","author":"Richter","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2026.101528_bib44","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","article-title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","volume":"12","author":"Brockelmann","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.resinv.2026.101528_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70138","article-title":"Cytomegalovirus infection after chimeric antigen receptor T-cell therapy or bispecific antibody treatment for hematologic malignancies","volume":"27","author":"Han","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.resinv.2026.101528_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-026-01484-0","article-title":"Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients","volume":"16","author":"Cheema","year":"2026","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.resinv.2026.101528_bib47","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.resinv.2026.101528_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106493","article-title":"Major pulmonary complications following hematopoietic stem cell transplantation: what the pulmonologist needs to know","volume":"185","author":"Shiari","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101528_bib49","unstructured":"TALVEY (talquetamab-tgvs) prescribing information. Janssen Biotech, Inc.; revised 2025."},{"key":"10.1016\/j.resinv.2026.101528_bib50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.resinv.2026.101528_bib51","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.resinv.2026.101528_bib52","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ajh.70339","article-title":"Integrating recent evidence and expert perspectives into the management of multiple myeloma: consensus recommendations from the 2025 bridging the Gaps Conference","volume":"101","author":"Chari","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2026.101528_bib53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12016-025-09116-4","article-title":"Bridging the gap in secondary antibody deficiencies: current evidence and unmet needs in diagnosis and management with immunoglobulin replacement","volume":"68","author":"Kan","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resinv.2026.101528_bib54","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1159\/000547111","article-title":"Bispecific T-cell engagers-induced interstitial lung disease: two case reports confirmed by transbronchial lung cryobiopsy","volume":"104","author":"Morviducci","year":"2025","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2026.101528_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2025.2499218","article-title":"Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system","author":"Liang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.resinv.2026.101528_bib56","series-title":"Genentech","year":"2025"},{"key":"10.1016\/j.resinv.2026.101528_bib57","series-title":"Genmab US\/AbbVie","year":"2026"},{"key":"10.1016\/j.resinv.2026.101528_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2026.101528_bib59","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.2025032352","article-title":"How I treat HLH-like toxicities after immune effector cell therapy","volume":"147","author":"Johnson","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2026.101528_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.12.947","article-title":"Immune effector cell-associated HLH-like syndrome (IEC-HS) in CAR-T and TCE-treated myeloma and B-cell malignancies: insights from a pharmacovigilance study","volume":"32","author":"Irfan","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.resinv.2026.101528_bib70","unstructured":"TECVAYLI (teclistamab-cqyv) prescribing information. Janssen Biotech, Inc.; revised 2026."},{"key":"10.1016\/j.resinv.2026.101528_bib71","series-title":"ELREXFIO (elranatamab-bcmm) prescribing information","year":"2026"},{"key":"10.1016\/j.resinv.2026.101528_bib72","series-title":"Regeneron Pharmaceuticals; revised","year":"2025"},{"key":"10.1016\/j.resinv.2026.101528_bib61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2014.58.0480","article-title":"Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis","volume":"33","author":"Chellapandian","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib62","article-title":"Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy","volume":"54","author":"Bauer","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101528_bib63","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/OP-24-00489","article-title":"Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration","volume":"21","author":"Sandahl","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.resinv.2026.101528_bib64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ejh.14444","article-title":"European expert panel consensus on outpatient administration of teclistamab and talquetamab in patients with multiple myeloma: feasibility, key considerations, and future directions","volume":"115","author":"Lund","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.resinv.2026.101528_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1630146","article-title":"A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma","volume":"15","author":"Garfall","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.resinv.2026.101528_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/03007995.2026.2626367","article-title":"Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers","volume":"42","author":"Derman","year":"2026","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.resinv.2026.101528_bib67","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101528_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603870","article-title":"Teclistamab in multiple myeloma with one to three previous lines of therapy","author":"Touzeau","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:30:22Z","timestamp":1792834222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526001620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2212534526001620"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101528","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxemia and pulmonary infiltrates during T-cell-engaging bispecific antibody therapy: A pulmonary and critical care framework","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101528"}}